Results 231 to 240 of about 40,867 (262)
Some of the next articles are maybe not open access.
Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study.
The Lancet Oncology, 2019BACKGROUND Giant-cell tumour of bone (GCTB) is a rare, locally aggressive osteoclastogenic stromal tumour of the bone. This phase 2 study aimed to assess the safety and activity of denosumab in patients with surgically salvageable or unsalvageable GCTB.
S. Chawla +14 more
semanticscholar +1 more source
The Lancet Oncology, 2019
BACKGROUND Denosumab is a fully human monoclonal antibody that binds to, and inhibits, the receptor activator of RANKL (TNFSF11) and might affect breast cancer biology, as shown by preclinical evidence.
R. Coleman +16 more
semanticscholar +1 more source
BACKGROUND Denosumab is a fully human monoclonal antibody that binds to, and inhibits, the receptor activator of RANKL (TNFSF11) and might affect breast cancer biology, as shown by preclinical evidence.
R. Coleman +16 more
semanticscholar +1 more source
Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone
Nature Reviews Rheumatology, 2023S. Ferrari, B. Langdahl
semanticscholar +1 more source
The Lancet Oncology, 2019
BACKGROUND In postmenopausal women with hormone receptor-positive, early-stage breast cancer, treatment with adjuvant aromatase inhibitors is the standard of care, but it increases risk for osteoporosis and fractures.
M. Gnant +18 more
semanticscholar +1 more source
BACKGROUND In postmenopausal women with hormone receptor-positive, early-stage breast cancer, treatment with adjuvant aromatase inhibitors is the standard of care, but it increases risk for osteoporosis and fractures.
M. Gnant +18 more
semanticscholar +1 more source